Dr. Linnstaedt and collaborators submitted an R61 grant application to further develop FKBP51 inhibitors as potential therapeutics for post traumatic chronic pain. Dr. McKibben submitted a K99/R00 application to fund her research focused on early life adversity as a risk factor for pain after trauma.